FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, specifically to therapeutic fusion proteins that can be used in medicine to treat type IIIB mucopolysaccharidosis (Sanfillipo B Syndrome). Said fusion protein contains (a) human alpha-N-acetylglucosaminidase (Naglu), (b) IGF-II mutein with a mutation that eliminates at least one protease cleavage site by furin in said IGF-II mutein, and (c) a spacer peptide between said lysosomal enzyme and said IGF-II mutein. Said spacer peptide contains an amino acid sequence selected from GGGGSGGGGSGGGGSGGGGSGGGPS, GAPGGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTGPSGAP, GAPGGGSPAPAPTPAPAPTPAPAGGGPSGAP, GAPGGGSPAEAAAKEAAAKEAAAKEAAAKEAAAKAPSGGGGAP and GGGGAGGGGAGGGGAGGGGAGGGPS.
EFFECT: invention effectively reduces the levels of glycosaminoglycans during treatment of type IIIB mucopolysaccharidosis (Sanfillipo B Syndrome).
20 cl, 3 dwg, 2 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC TARGETED FUSION PROTEINS BASED ON LYSOSOMAL ENZYMES, RELEVANT COMPOSITIONS AND THEIR APPLICATIONS | 2017 |
|
RU2751235C2 |
| COMPOSITIONS AND METHODS OF USING FOR TREATING METABOLIC DISORDERS | 2014 |
|
RU2704285C2 |
| RECOMBINANT IMMUNOTOXIN AIMED AT MESOTHELIN | 2012 |
|
RU2600067C2 |
| NOVEL POLYPEPTIDES | 2014 |
|
RU2674604C2 |
| IMPROVED METHODS OF PRODUCING RECOMBINANT POLYPEPTIDE | 2014 |
|
RU2711322C1 |
| ANTI-IGF-1R ANTIBODY AND USE THEREOF AS AN ADDRESS VECTOR FOR CANCER TREATMENT | 2015 |
|
RU2698977C2 |
| DIAGNOSTIC ASSAYS AND KITS FOR DETECTION OF FOLATE RECEPTOR 1 | 2013 |
|
RU2668824C2 |
| PRODUCTION OF HIGH-MANNOSE PROTEINS IN VEGETABLE CULTURES | 2004 |
|
RU2385928C2 |
| MODIFIED EXOTOXIN A PSEUDOMONADES | 2014 |
|
RU2687143C2 |
| IL-12 COMPOSITIONS AIMED AT EDB | 2019 |
|
RU2758143C1 |
